About Us
About hVIVO
Leadership Team
Our Companies
History
Services
Human Challenge Trials
RSV
Influenza
COVID-19
HRV
Malaria
Asthma & COPD
hMPV
Laboratory Services
Clinical Trial Recruitment
Clinical Trial Site Services
Vaccine Phase II-III Trials
Respiratory Clinical Trials
Articles & Research
News & Media
Regulatory News
Media Coverage
Media Press Kit
Media Library
Events
Investors
Investors
Regulatory News & Email Alerts
Results Centre
Share Price Information
Events & Presentations
Environmental, Social & Governance
AIM Rule 26
Advisors
Documents
Corporate Governance
Volunteers
Careers
Contact Us
Contact Us
11 Sep 2023
Go Back
Pharma Focus Asia, Issue 52, 2023 – Human Challenge Trials: Establishing early risk-benefit in development of vaccines and therapies for infectious diseases
Share this:
Featured on pages 54-56
Other recent posts
Case Study
World-leading Expertise in Challenge Studies Supports the Successful Delivery of a Large-scale Outpatient Vaccine Study in Healthy Participants.
View Link
Presentation
Assessing Immunomodulators in Human Challenge Studies Insights from Wild-Type Influenza Infections in Healthy Adults and Rhinovirus Infections in Patients with Asthma
View Link
If you’re a potential customer, job seeker, health professional or an investor, find out how hVIVO can help you.
Contact hVIVO
print
twitter
facebook
envelope
linkedin
angle-down
xing
paper-plane
pinterest-p
whatsapp
commenting
meetup
chevron-down
arrow-up
